{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=4",
    "query": {
      "intervention": "Formulation #1",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 1757,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%231&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T15:52:14.394Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00652496",
      "title": "Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Bimatoprost 0.01% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.015% formulation 1 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.015% formulation 2 ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.02% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Bimatoprost 0.03% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 249,
      "start_date": "2005-01",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2008-04-03",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 1,
      "location_summary": "Wenatchee, Washington",
      "locations": [
        {
          "city": "Wenatchee",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00652496"
    },
    {
      "nct_id": "NCT02136940",
      "title": "Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension",
        "Eye Disease"
      ],
      "interventions": [
        {
          "name": "AMA0076",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amakem, NV",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "30 Years to 85 Years"
      },
      "enrollment_count": 103,
      "start_date": "2014-04",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-21",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 9,
      "location_summary": "Artesia, California • Inglewood, California • Petaluma, California + 6 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Morrow",
          "state": "Georgia"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02136940"
    },
    {
      "nct_id": "NCT04360174",
      "title": "CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ocular Hypertension",
        "Open Angle Glaucoma"
      ],
      "interventions": [
        {
          "name": "OTX-TIC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2018-04-25",
      "completion_date": "2021-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 5,
      "location_summary": "Petaluma, California • Torrance, California • Roswell, Georgia + 2 more",
      "locations": [
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Roswell",
          "state": "Georgia"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Racine",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04360174"
    },
    {
      "nct_id": "NCT03699124",
      "title": "Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Smallpox"
      ],
      "interventions": [
        {
          "name": "FD MVA-BN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 1129,
      "start_date": "2019-06-19",
      "completion_date": "2020-06-22",
      "has_results": true,
      "last_update_posted_date": "2021-05-27",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Melbourne, Florida • Peoria, Illinois + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699124"
    },
    {
      "nct_id": "NCT02762370",
      "title": "Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Knee",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "FX006 32 mg",
          "type": "DRUG"
        },
        {
          "name": "TCA IR 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2016-04",
      "completion_date": "2016-11",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 8,
      "location_summary": "Anaheim, California • El Cajon, California • North Hollywood, California + 5 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "Duncansville",
          "state": "Pennsylvania"
        },
        {
          "city": "Mt. Pleasant",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02762370"
    },
    {
      "nct_id": "NCT00870103",
      "title": "Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2008-09",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2010-03-09",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00870103"
    },
    {
      "nct_id": "NCT02077803",
      "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR, 500 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg",
          "type": "DRUG"
        },
        {
          "name": "CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 47,
      "start_date": "2014-03",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-09-03",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02077803"
    },
    {
      "nct_id": "NCT02823483",
      "title": "18348-Human Phototoxicity Test",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sunscreening Agents"
      ],
      "interventions": [
        {
          "name": "Sunscreen Lotion (BAY987521)",
          "type": "OTHER"
        },
        {
          "name": "Untreated Skin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 35,
      "start_date": "2015-11",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-07-06",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 1,
      "location_summary": "Piscataway, New Jersey",
      "locations": [
        {
          "city": "Piscataway",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02823483"
    },
    {
      "nct_id": "NCT03817320",
      "title": "PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "ALL, Childhood",
        "Lymphoblastic Lymphoma, Childhood",
        "Lymphoblastic Leukemia, Acute, Childhood"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate (IT)",
          "type": "DRUG"
        },
        {
          "name": "Triple IT (Methotrexate, Hydrocortisone, Cytarabine)",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-02-12",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-17",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03817320"
    },
    {
      "nct_id": "NCT06204679",
      "title": "Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer Study"
      ],
      "interventions": [
        {
          "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions",
          "type": "DRUG"
        },
        {
          "name": "Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions",
          "type": "DRUG"
        },
        {
          "name": "Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atea Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 42,
      "start_date": "2023-12-14",
      "completion_date": "2024-08-25",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-30T15:52:14.394Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06204679"
    }
  ]
}